Obesity induced by high-fat (HF) feeding is associated with low-grade inflammation in peripheral tissues that predisposes to insulin resistance. Recent evidence suggests the occurrence of a similar process in the hypothalamus, which favors weight gain through impairment of leptin and insulin signaling. In addition to its implications for obesity pathogenesis, this hypothesis suggests that centrally targeted antiinflammatory therapies may prove effective in prevention and treatment of this disorder. This article highlights molecular and cellular mechanisms by which hypothalamic inflammation predisposes to diet-induced obesity. A s the first decade of the new millennium comes to a close, obesity remains a leading public health problem due to its association with diabetes, cardiovascular disease, and other comorbidities. Although rapid, recent increases of overweight/obesity prevalence may finally be slowing (1), 68% of U.S. adults have a body mass index greater than 25 kg/m 2 and collectively account for an estimated 10% of annual health care costs (ϳ$147 billion in 2008) (2). Exacerbating this problem is a lack of effective obesity treatment options. Neither diet-and exercisebased lifestyle interventions nor pharmacological therapies have met with large-scale success (3, 4), and although bariatric surgical procedures yield sustained reductions of morbidity and mortality in randomized trials (5, 6), they carry significant risk and can realistically be offered to only a small number of obese individuals. New strategies to combat the obesity epidemic are urgently needed, but gaps in our understanding of obesity pathogenesis continue to limit progress toward this goal.
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Energy homeostasis and obesity pathogenesis
Although it seems intuitively obvious that switching to a highly palatable, energy-dense diet would favor weight gain, diet-induced obesity (DIO) in both humans and rodent models involves a change in energy homeostasis characterized by an increase in the defended level of body fat stores (7) (8) (9) , and models forwarded to explain obesity pathogenesis must take this phenomenon into account. After the cloning of leptin in 1994 and subsequent characterization of its actions in the hypothalamus, insight into molecular pathways governing energy homeostasis has grown at a rapid pace (reviewed in Refs. 10 and 11). Leptin, secreted by adipocytes in proportion to body fat mass, serves as a circulating signal of energy stores in part by providing feedback inhibition of hypothalamic orexigenic pathways [e.g. neurons that express neuropeptide Y and agouti-related peptide (AgRP)] and stimulating anorexigenic neurons, including those that express proopiomelanocortin (POMC). Although rare forms of monogenic obesity stem from genetic defects in leptin or POMC signaling pathways (12) , human obesity more commonly results from complex interactions between a large number of gene variants and a host of environmental/lifestyle variables. These interactions set the stage for two cardinal features of obesity: energy intake in excess of energy requirements and the biological defense of an elevated level of body fat mass.
Although the mechanisms responsible for the latter phenomenon remain uncertain, acquired leptin resistance is implicated as a factor that predisposes to DIO in rodent models. Obesity is strongly associated with hyperleptinemia in both humans and rodents placed on a high-fat diet (HFD), and exogenous leptin is relatively ineffective in reducing food intake or body weight in both species once obesity is established. These observations support a model in which DIO arises at least in part from a failure of key hypothalamic neurocircuits to respond to the stop signal provided by leptin, analogous to the central and peripheral insulin resistance that occurs in this setting (13) (14) (15) . Indeed, mechanisms underlying obesity-induced insulin resistance at the cellular level can also impair leptin signaling (13) (14) (15) (16) (17) . What has proven challenging, however, is to determine whether leptin resistance truly causes common forms of obesity or is merely a consequence of excess weight gain. Recent work reviewed herein has begun to resolve this question.
In peripheral tissues, the deleterious metabolic consequences of obesity arise in part via cellular inflammation triggered by nutrient excess (Fig. 1 ) (14 -19) . Excess visceral adiposity is accompanied by chronic low-grade inflammation affecting liver, adipose tissue, skeletal muscle, and the vasculature and is ultimately accompanied by increased circulating levels of proinflammatory cytokines and acute-phase reactants. Although this inflammatory process is initiated via cell-autonomous mechanisms, the subsequent infiltration of immune cells such as macrophages, dendritic cells, and T cells into key metabolic tissues generates an inflammatory milieu that further disrupts insulin receptor signal transduction (20 -22) . In addition, signals from Toll-like receptors (TLRs), evolutionarily conserved pattern recognition molecules critical for detecting pathogens, amplified through signaling intermediates such as MyD88 activate the inhibitor of Bkinase-␤ (IKK␤)/nuclear factor-B (NF-B), c-Jun N-terminal kinase (Jnk) and other intracellular inflammatory signals in response to stimulation by circulating saturated fatty acids (23) , exacerbating the inflammatory response and associated insulin resistance. Thus ensues a vicious cycle of inflammation and impaired nutrient use that produces progressive, systemic metabolic impairment predisposing to diabetes, steatohepatitis, and atherosclerosis (Fig. 1 ).
In the context described above, failure of metabolic homeostasis arises as a result of obesity and does not play a causal role in excess weight gain itself. Thus, successful antiinflammatory interventions targeted to macrophages or peripheral organs result in dissociation of obesity and insulin resistance rather than resolution of both (15) . In this review, we present evidence supporting the hypothesis that, in contrast to the peripheral response, hypothalamic inflammation resulting from HFD consumption contributes to obesity pathogenesis through the development of central leptin and insulin resistance.
High-fat (HF) feeding and hypothalamic inflammation
In 2005 evidence first emerged that inflammatory changes are detectable in the brain of HFD-fed animals. A 20-wk HFD-feeding study reported increased reactive oxygen species and prostaglandin E2 production along with up-regulation of NF-B signaling in the rat cerebral cortex (24) . Focusing on the hypothalamus, De Souza et al. (25) demonstrated that immune-related molecules, including the canonical proinflammatory cytokines, IL-1␤, TNF␣, and IL-6, represent the largest class of genes with altered hypothalamic expression levels after 16 wk of HFD. Underlying these responses are activation of both Jnk (25) and the IKK␤/NF-B pathway as well as induction of endoplasmic reticulum (ER) stress (26 -29) over a time frame that parallels the onset of reduced hypothalamic leptin sensitivity in rodent models of DIO (30, 31) . The association of DIO with both higher serum levels of insulin and leptin and increased activation of inflammatory signaling pathways raises the possibility that these two alterations are causally linked. However, animals lacking leptin signaling are obese and hyperphagic and manifest an even greater degree of inflammatory changes in the periphery and hypothalamus than do DIO animals (29) . Thus, changes in hormone levels appear to be a response to weight gain-associated resistance rather than a driver of HFD-associated inflammation and obesity.
Hypothalamic inflammation contributes to HFD-induced obesity
Consistent with a causal role for hypothalamic inflammation in HFD-induced obesity, neuron-specific disruption of either the TLR4/MyD88 or IKK␤/NF-B pathways protects against DIO, hypothalamic leptin resistance, and systemic insulin resistance (29, 32) . Moreover, viral strategies to either delete IKK␤ or overexpress a dominantnegative IKK␤ isoform specifically in mediobasal hypo- The vicious cycle of obesity and diabetes. Energy intake in excess of energy requirements leads to a state of chronic nutrient excess that causes cellular inflammation in both peripheral tissues and the hypothalamus. The resulting activation of inflammatory pathways generates insulin and leptin resistance ultimately promoting obesity and diabetes. Therapies that prevent hypothalamic inflammation may disrupt these interlinked vicious cycles with consequent improvements in energy and glucose homeostasis.
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Thaler and Schwartz Hypothalamic Inflammation and Obesity Endocrinology, September 2010, 151(9):4109 -4115 thalamic neurons also reduce food intake and weight gain during HF feeding, confirming that the phenotypes of congenital knockouts are not a result of altered hypothalamic development (29) . In genetically normal animals, central infusion of either a specific inhibitor of IKK␤ or antibodies to TLR4 can reduce food intake (and body weight in the latter case) in rats made obese by HFD (26, 28) but not in controls fed standard chow. These studies identify hypothalamic inflammation as an important, potentially reversible cause of HFD-induced weight gain (Fig. 1 ).
Complementing these findings is evidence that interventions that augment hypothalamic inflammation predispose to HFD-induced obesity. For one, neuronal expression of a constitutively active IKK␤ isoform (29) increases food intake. Furthermore, we have found that infusion of the Th2 cytokine IL-4 directly into the brain of rats fed HFD exerts a paradoxically proinflammatory effect on the hypothalamus (which is not observed in rats fed standard chow) that exacerbates weight gain in an IKK␤-dependent manner (33) . These data collectively suggest that hypothalamic inflammation is both necessary and sufficient for initial and sustained weight gain during HF feeding and thus represents an important new target for obesity therapeutics. Interestingly, in a recent retrospective case-control study, use of antiinflammatory therapy (statin or aspirin) was associated with a 2-fold increase in the likelihood of weight loss in patients with type 2 diabetes at 1 yr of follow-up (34).
Mechanisms linking hypothalamic inflammation to HFD-induced weight gain
As described above, DIO is hypothesized to result in part from hypothalamic resistance to the weight-reducing effects of leptin and insulin. In this regard, inflammatory signaling can influence hypothalamic leptin and insulin action in several ways. Although ligands for structurally distinct receptors, both leptin and insulin signal through common downstream pathways including the insulin receptor substrate protein (IRS)-phosphatidylinositol-3 kinase and MAPK pathways (11, 13) . In addition, leptin (but not insulin) alters gene expression through activation of the Janus kinase (Jak)-signal transducer and activator of transcription (STAT)-3 pathway. In peripheral tissues, IKK␤ and Jnk1 can serine-phosphorylate IRS molecules rendering them unable to transduce signals downstream of insulin receptors (14 -16) . Similarly, hypothalamic overexpression of a constitutively active IKK␤ isoform reduces both insulin and leptin signaling (29) ; conversely, intracerebroventricular administration of an IKK␤ inhibitor reverses HFD-induced hypothalamic insulin resistance (28) , and neuron-specific deletion of either IKK␤ or MyD88 maintains leptin and insulin sensitivity in HFDfed mice (29, 32) .
By comparison, the role of neuronal Jnk1 in HFD-induced obesity remains unclear. Although hypothalamic Jnk1 is induced by HF feeding (32) and total body Jnk1 knockouts are resistant to DIO, neuron-specific Jnk1 knockout mice were reported by one group to have growth retardation and improved insulin sensitivity but intact susceptibility to HFD-induced leptin resistance and weight gain (32, 35) , whereas another group found them to be DIO resistant due to up-regulation of the hypothalamuspituitary-thyroid axis (36) . Further studies on the function of neuronal Jnk1 in energy balance regulation await targeted approaches that preserve pituitary Jnk1 activity.
Another mechanism through which hypothalamic inflammation is linked to leptin and insulin resistance is via up-regulation of suppressor of cytokine signaling (SOCS)-3. A member of a protein family originally characterized as negative feedback regulators of inflammation (13, 37) , SOCS3 inhibits insulin and leptin signaling both by direct binding to their cognate receptors and targeting IRS proteins for proteasomal degradation (13, 37) . HF feeding increases SOCS3 expression specifically within the arcuate nucleus of the hypothalamus coincident with the onset of leptin resistance selectively in this brain area (31) . The mechanism underlying increased SOCS3 expression during HF feeding is uncertain because it can be induced via either leptin-Jak/STAT or IKK␤/NF-B pathways.
Conversely, both SOCS3 haploinsufficiency and neuron-specific SOCS3 deletion protect mice from DIO by increasing leptin sensitivity (38, 39) , whereas overexpression of SOCS3 in POMC neurons (either directly or by increasing STAT3 activation) results in hyperphagia and obesity on a chow diet (40, 41) . Linking SOCS3 to inflammation, HFD-resistant neuronal IKK␤ knockout mice show greatly reduced SOCS3 expression in the hypothalamus, whereas misexpression of SOCS3 in the mediobasal hypothalamus abolishes the protection from HFD-induced obesity in AgRP-neuron-specific IKK␤ knockout animals (29) . Future experiments are needed to identify mechanisms underlying the hypothalamus-specific increase of SOCS3 expression observed during highfat feeding (31) and to determine whether HFD-induced weight gain caused by augmenting hypothalamic inflammation requires functional SOCS3 signaling.
Like SOCS3, the protein tyrosine phosphatase (PTP)-1B is a signal termination molecule that inhibits both leptin and insulin signaling. The mechanism underlying these effects involves its ability to dephosphorylate the insulin receptor, Jak2, and more distal components of both pathways (42) , and available data suggest HF feeding increases PTP1B expression in several tissues including the hypo- thalamus (42, 43) . That this effect is recapitulated by systemic TNF␣ administration suggests that functional interactions exist between inflammatory signaling and PTP1B activation (42) . Pan-neuronal (44) or POMC neuron-specific (45) PTP1B knockout mice are resistant to DIO due to enhanced hypothalamic leptin and insulin sensitivity, but whether and how this response might be related to altered hypothalamic inflammatory signaling awaits further study. Because both pan-neuronal PTP1B knockout mice and rats with hypothalamic PTP1B knockdown show equivalent reductions of food intake whether fed chow or HFD (44, 46) , this protein may favor weight gain via mechanisms in addition to those involving hypothalamic inflammation. The unfolded protein response (UPR), an important inflammation-associated mechanism induced by ER stress, may also contribute to both HFD-induced hypothalamic inflammation and associated leptin and insulin resistance. Augmentation of the UPR in response to nutrient excess is a major cause of HFD-induced dysregulation of peripheral tissue metabolism (19) , and a similar process may occur in the hypothalamus (26, 27, 29) . In the periphery, components of the UPR trigger both Jnk and IKK␤/NF-B activation, further fueling the inflammatory effect of HFD (19) , and inflammatory signals may potentially feed back to exacerbate ER stress, although this issue remains unresolved. In support of this concept is evidence that expression of a constitutively active IKK␤ isoform in mediobasal hypothalamus increases ER stress, whereas neuron-specific IKK␤ knockout mice manifest a reduced UPR (29) , although these effects are potentially confounded by associated changes of food intake and body weight. Importantly, ER stress inhibitors restore leptin sensitivity to HFD-fed mice and lower both food intake and body weight in obese animals (27, 29) . Conversely, induction of ER stress using the antibiotic tunicamycin or by deleting X-box binding protein-1 in neurons results in hyperleptinemia, obesity, hyperphagia, and reduced metabolic rate associated with severe hypothalamic leptin resistance (27) . If ER homeostasis is not restored (as might be expected with continued HFD exposure), the UPR culminates with the induction of apoptosis, a finding recently described in hypothalamus (47) , although both the functional relevance of this finding and its link to ER stress remain untested.
Although beyond the scope of this review, it is clear that inflammation in the hypothalamus can have widely varying behavioral outcomes, depending on the context, time frame, and amplitude of the response. Thus, substantial elevations of hypothalamic cytokine levels as observed in animal models of sepsis produce profound anorexia in both leptin-dependent and -independent manners (48, 49). However, low-grade inflammation generated by HF feeding or experimentally by central administration of low levels of TNF␣, for example, correlates with impaired rather than increased leptin and insulin-mediated anorexia (50) . The nature of this divergent response remains unclear but may depend more on the different cellular origins and/or sites of action of inflammation rather than the specific signals involved [reviewed by these authors here (51)].
Mechanisms linking diet with inflammation
A cohesive picture has yet to emerge from attempts to determine how HFD induces hypothalamic inflammation. Indeed, the question of whether hypothalamic inflammation simply results from consumption of energy in excess of caloric needs irrespective of diet composition has yet to be definitively addressed. One potential mechanism that has received attention is the effect of saturated, but not unsaturated, fatty acids to activate TLR4/NF-B signaling. The saturated fatty acid palmitate (16:0) induces NF-B signaling through a TLR4-dependent mechanism both when administered in neuronal cell culture and after infusion directly into the brain (32, 52, 53) , and the latter intervention also induces leptin and insulin resistance. However, studies using central infusion of saturated fatty acid treatments must be interpreted with caution because saturated fatty acids can have considerable cellular toxicity, even when administered at relatively physiological concentrations (ϳ200 -500 M).
Despite this support for palmitic acid as a putative mediator of hypothalamic inflammation, a recent comprehensive survey of long-chain fatty acids infused into the brain found no effect of palmitic acid (16:0), whereas 18:0 (stearic) and longer saturated fatty acids as well as linolenic acid (18:3) increased proinflammatory cytokines, ER stress markers, and TLR4 activation (26) . Likewise, a recent study using palmitic acid treatment of hypothalamic cell lines revealed no evidence of increased inflammatory signaling but instead robust induction of ER stress (54) . Combined with a large number of studies showing that rodents gain equivalent amounts of weight on oleic acid/ vegetable fat-enriched diets vs. diets rich in saturated fat, questions persist about the differential inflammatory properties of distinct fatty acid constituents of the diet and their implications for energy homeostasis (26, 55) . Although HFD has been shown to increase endogenous endotoxin levels, a potential contributor to DIO (33) , it is unclear whether this effect is limited to fat-rich diets. Nevertheless, animals exposed to HFD have an exaggerated response to endotoxin administration with increases in hypothalamic expression of proinflammatory cytokines and SOCS3, a potential mechanism linking HFD, hypothalamic inflammation, and weight gain (56) .
Central nervous system (CNS) cell types involved in HFD-induced inflammation
One key unresolved question regarding HFD-induced inflammation in the CNS is the nature of the cell types and brain regions involved in the response. This information is vital not only to understanding the mechanisms underlying obesity pathogenesis and identifying potential targets for obesity therapeutics but also for efforts to understand how inflammation during HF feeding (which is accompanied by increased food intake and body weight) differs from that induced by sickness or brain injury (typically associated with negative energy balance and weight loss) (51) . Although some evidence suggests inflammation within specific hypothalamic neurons (e.g. AgRP neurons) (29) is critical for disrupting leptin and insulin signaling and favoring weight gain, a thorough analysis of the cell types responsible for initiating and propagating this inflammatory response has yet to be conducted. In addition, both the regional specificity and the time course of this response within the CNS remain to be characterized.
A key unanswered question is whether hypothalamic inflammation induced by HFD originates within neurons or whether immune cells such as microglia may play a role. If HFD-induced inflammation is restricted to neurons, what factors confer susceptibility to this response? Certainly not all neurons are susceptible. Although IKK␤ signaling in discrete neuronal subsets appears to be required for both hypothalamic inflammation and excess weight gain to occur during HF feeding (29) , whether this inflammation is prompted by microglial activation (analogous to the recruitment and activation of adipose tissue macrophages) remains an open question.
Going forward, cell-specific approaches using conditional mutants and cell separation techniques should help to clarify the role of the various CNS cell types in the genesis of hypothalamic inflammation induced by distinct stimuli. Of interest in this regard is the paradoxical observation that hyperphagia and weight gain occur when hypothalamic inflammation is induced by HF feeding, yet when it occurs in response to systemic or local inflammatory processes (e.g. administration of endotoxin), anorexia and weight loss are the rule. A plausible but untested hypothesis to explain this paradox proposes that neurons are the primary target of HFD-induced hypothalamic inflammation, whereas immune cells are the first responders to other, more potent inflammatory stimuli.
Summary
HF feeding induces inflammatory signaling in not only a multitude of peripheral tissues, resulting in insulin resistance, but also the hypothalamus, causing local resistance to both insulin and leptin. Unlike the situation in peripheral tissues, interventions that limit hypothalamic inflammatory signaling can prevent obesity from developing, implicating the latter as cause rather than just a consequence of obesity. Pharmacological interventions that block hypothalamic inflammation during HF feeding therefore have potential in obesity prevention and treatment (Fig. 1) . To date, antiinflammatory treatments have failed to produce significant changes in body weight, although some have improved insulin sensitivity (57, 58) . These efforts have perhaps been limited by difficulties inherent in disrupting IKK␤ signaling in the CNS and therapeutic approaches that target individual cytokines rather than cellular processes. As the mechanisms linking hypothalamic inflammatory signaling to leptin and insulin resistance become better understood, including activation of TLR4/IKK␤/NF-B signaling and induction of SOCS3 and ER stress, so too will their potential as targets for obesity treatment and prevention.
